S-1 · primary offering
Issued 2026
Proposed maximum
Shares registered
- Filed
- Effective
VBIO$0.5499+3.58%
Valion Bio, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$1.19M
Float & O/S:
Inst Own:
DilutionScan read 50 of Valion Bio, Inc.'s SEC filings and found 28 warrant series, 4 convertibles, 2 ATM programs, 2 equity lines, 9 shelf registrations, 3 S-1 registrations and 10 completed offerings on file for VBIO. Analysis updated Oct 27, 2026.
Signal8 Summary
VBIO
Going-concern warning, near-zero cash, severe dilution
- Business
- WeakNo revenue, $2.1M cash vs $17.4M debt, going-concern warning
- Stock risk
- High$2.4M micro-cap, 1-for-25 split, shares +302% YoY
Snapshot
Valion Bio is a clinical-stage biotech with no revenue, a $7.9M operating loss and an $8.9M net loss in the latest fiscal year, and only $2.1M in cash against $17.4M of debt.
What's Happening Right Now
- : Valion filed a $100M shelf plus a $5M at-the-market offering, capped near $5M/year by SEC rules given its small market value, while its auditor flags going-concern doubt.
- : Registered $100.00M of securities for sale on Form S-3.
- : Nasdaq confirmed Valion regained compliance with the minimum bid price rule, closing out the delisting threat for now.
- : The latest 10-Q disclosed a $7.1M quarterly net loss, cash down to $2.1M, an explicit going-concern warning, and non-compliance with Nasdaq's minimum bid price rule.
- : Investor 3i, LP filed an amended 13D laying out up to $9M more funding tied to ousting CEO Michael Handley and installing its own nominees as Chairman and directors.
- : Raised $7.74M in gross proceeds through a private placement (PIPE), with warrants over 1.06M shares.
- : The board declared a 1-for-25 reverse stock split effective Aug 31, 2026 to regain Nasdaq compliance.
- : Raised $1.50M in gross proceeds through a private placement (PIPE), with warrants over 46K shares.
Raise routes on file: active ATM + effective shelf + effective S-1 + active equity line · latest dilution event 8 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Oct 26, 2026 · Offering Priced
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Withdrawn
S-1 · resale registration
Issued 2026
Proposed maximum
Shares registered
- Filed
- Effective
S-1 · resale registration
Issued 2025
Proposed maximum
Shares registered
- Filed
- Effective
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2023
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Series A Non-Voting Convertible Preferred Stock
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Series B Non-Voting Convertible Preferred Stock
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Series C Non-Voting Convertible Preferred Stock
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
ATM program
Issued 2026
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
ATM program
Issued 2024
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
Equity line
Issued 2026
Commitment
Sold to date
Remaining
- Agreement date
- Term ends
- Discount
Equity line
Issued 2025
Commitment
Sold to date
Remaining
- Agreement date
- Term ends
- Discount
S-3 shelf registration
Issued 2026
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2026
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2025
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2025
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2025
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2025
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
PIPE
Issued 2025
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Issued 2025
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Offering
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Offering
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your VBIO trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
